Cooper Companies (The) (COO) fundamentals: P/E, valuation, undervalued?
Cooper Companies (The) · Health Care · ref. ETF XLV · price $70.96
In short — Cooper Companies (The) trades at 61.7× earnings (P/E), 14.2× forward, with a net margin of 5.6 % and revenue growth of +8 %. Read: Very high P/E (P/E 62 (well above average)).
Is Cooper Companies (The) stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$70.96+9.9% over range
Aug 28, 25low $58.98 · high $84.32Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
64% recommend buying · 11 analysts
Valuation : Very high P/E — P/E 62 (well above average)
Valuation
61.7
P/E (price/earnings)
14.2
Forward P/E
—
PEG
1.7
Price/book (P/B)
—
Market cap
1.15
EPS
Profitability & growth
5.6 %
Net margin
+8 %
Revenue growth
—
Earnings growth
$2.7B
Total debt
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Cooper Companies (The)'s P/E and is the stock undervalued? What's a good P/E?
Cooper Companies (The)'s P/E is 61.7 (forward 14.2). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Very high P/E".
Is Cooper Companies (The) profitable?
Cooper Companies (The) has a net margin of 5.6 % (EPS 1.15). The company is profitable.
Is COO stock expensive?
Our read: "Very high P/E" — P/E 62 (well above average). Cross-check with growth and sector.
💬 A question about Cooper Companies (The)? The JPI assistant answers using our backtest data.
Keep exploring Cooper Companies (The)